NeuroIntact
NeuroIntact is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at NeuroIntact.
NeuroIntact is a company.
Key people at NeuroIntact.
Key people at NeuroIntact.
NeuroIntact, Inc. is a Baltimore-based med-tech startup founded in 2023, specializing in non-invasive targeted temperature management (TTM) solutions to preserve brain function in patients with traumatic brain injury (TBI), stroke, cerebral edema, and related conditions.[1][3][5] The company develops the patented VCool™ TTM system and ICEPICC device, using intranasal cooling via nasal cannulation to rapidly reduce intracranial pressure and control core temperature without sedation, shivering, or systemic side effects, serving military personnel, critical care providers, and civilian patients.[1][3][5][6] Backed by a $250,000 TEDCO Seed Funds investment in October 2024 and partnerships like licensing Vivonics' technology, NeuroIntact shows early growth momentum toward FDA clearance and commercialization.[1][4]
NeuroIntact was founded in 2023 by Bryan Nicholson, its visionary CEO and President, who leads with expertise in the TTM market and a focus on deployable brain cooling solutions.[1][2][3][5] The idea emerged from recognizing gaps in current TBI and stroke treatments, particularly the need for rapid, non-invasive cooling to protect neurological function in combat and civilian settings—spurred by insights into soldier brain injuries through partnerships.[1][6] A pivotal moment came with licensing Vivonics' intra-nasal brain cooling technology (ICEPICC), supported by a US Marine Corps grant and Vivonics' $999,962 SBIR contract, enabling full product development.[1][2][6] Early traction includes TEDCO's $250,000 investment in 2024 and assembling a strong board.[3][4]
NeuroIntact rides the wave of advanced neuromedicine and TTM innovation, addressing surging demand for TBI/stroke treatments amid rising military conflicts, aging populations, and post-pandemic brain health focus.[1][3][6] Timing is ideal: limitations of systemic cooling (e.g., side effects, slow deployment) create a market gap, while intranasal tech leverages proven TTM benefits with portability for field use—potentially shifting paradigms in combat trauma and ER care.[2][3][6] Favorable forces include public-private funding (USMC SBIR, TEDCO) and med-tech trends toward non-invasive devices; NeuroIntact influences the ecosystem by bridging military R&D to civilian applications, enhancing outcomes via faster neurological protection.[1][4][6]
NeuroIntact is poised for FDA clearance and market entry with VCool™/ICEPICC, fueled by recent board additions, funding, and Vivonics partnership—targeting commercialization in 2025-2026.[1][3][5] Trends like AI-enhanced diagnostics, expanded TBI research, and portable med-tech will shape its path, potentially capturing share in the $2B+ TTM market while influencing military-civilian care standards.[3][6] Its influence may evolve from niche innovator to TTM leader, revolutionizing brain preservation as non-invasive therapies gain traction—echoing its founding mission to maintain neurological intactness for more patients.[1][5]
